Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

35 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Long-term follow up of the combination of ofatumumab, high-dose methylprednisolone, and lenalidomide for untreated chronic lymphocytic leukemia with biomarker analysis.
Chavez JC, Grajales A, Sandoval-Sus J, Turba E, Nodzon L, Uriepero-Palma A, Ammad-Ud-Din M, Sahakian E, Komrokji R, Sokol L, Locke FL, Shah B, Lancet J, Sotomayor EM, Kharfan-Dabaja MA, Bello C, Pinilla-Ibarz J. Chavez JC, et al. Among authors: sandoval sus j. Clin Lymphoma Myeloma Leuk. 2024 Feb 13:S2152-2650(24)00060-0. doi: 10.1016/j.clml.2024.02.001. Online ahead of print. Clin Lymphoma Myeloma Leuk. 2024. PMID: 38508880 Free article.
Bruton's Tyrosine Kinase Inhibitors: Recent Updates.
Fares A, Carracedo Uribe C, Martinez D, Rehman T, Silva Rondon C, Sandoval-Sus J. Fares A, et al. Among authors: sandoval sus j. Int J Mol Sci. 2024 Feb 12;25(4):2208. doi: 10.3390/ijms25042208. Int J Mol Sci. 2024. PMID: 38396884 Free PMC article. Review.
Efficacy of CD19 directed therapies in patients with relapsed or refractory large b-cell lymphoma relapsing after CD19 directed chimeric antigen receptor T-cell therapy.
Iqbal M, Jagadeesh D, Chavez J, Khurana A, Rosenthal A, Craver E, Epperla N, Li Z, Isufi I, Awan FT, Dholaria BR, Maakaron JE, Sandoval-Sus JD, Mishra R, Saha A, Annunzio K, Bhaskar ST, Sumransub N, Fijalka A, Ivanov SA, Lin Y, Kharfan-Dabaja MA. Iqbal M, et al. Among authors: sandoval sus jd. Bone Marrow Transplant. 2024 Feb;59(2):211-216. doi: 10.1038/s41409-023-02148-4. Epub 2023 Nov 16. Bone Marrow Transplant. 2024. PMID: 37973893
High-grade B-cell lymphoma, not otherwise specified: a multi-institutional retrospective study.
Zayac AS, Landsburg DJ, Hughes ME, Bock AM, Nowakowski GS, Ayers EC, Girton M, Hu M, Beckman AK, Li S, Medeiros LJ, Chang JE, Stepanovic A, Kurt H, Sandoval-Sus J, Ansari-Lari MA, Kothari SK, Kress A, Xu ML, Torka P, Sundaram S, Smith SD, Naresh KN, Karimi YH, Epperla N, Bond DA, Farooq U, Saad M, Evens AM, Pandya K, Naik SG, Kamdar M, Haverkos B, Karmali R, Oh TS, Vose JM, Nutsch H, Rubinstein PG, Chaudhry A, Olszewski AJ. Zayac AS, et al. Among authors: sandoval sus j. Blood Adv. 2023 Nov 14;7(21):6381-6394. doi: 10.1182/bloodadvances.2023009731. Blood Adv. 2023. PMID: 37171397 Free PMC article.
Frontline treatment approaches in TP53-aberrant mantle cell lymphoma.
Shah NN, Castillo-Tokumori F, Whiting J, Boulware D, Sandoval-Sus J, Knepper TC, Hussaini M, Tao J, Chavez JC, Isenalumhe L, Gaballa S, Saeed H, Bello C, Sokol L, Pinilla-Ibarz J, Shah BD. Shah NN, et al. Among authors: sandoval sus j. Leuk Lymphoma. 2023 Jan;64(1):230-233. doi: 10.1080/10428194.2022.2131407. Epub 2022 Oct 27. Leuk Lymphoma. 2023. PMID: 36301721 No abstract available.
An international analysis evaluating frontline bendamustine with rituximab in extranodal marginal zone lymphoma.
Alderuccio JP, Arcaini L, Watkins MP, Beaven AW, Shouse G, Epperla N, Spina M, Stefanovic A, Sandoval-Sus J, Torka P, Alpert AB, Olszewski AJ, Kim SH, Hess B, Gaballa S, Ayyappan S, Castillo JJ, Argnani L, Voorhees TJ, Saba R, Chowdhury SM, Vargas F, Reis IM, Kwon D, Alexander JS, Zhao W, Edwards D, Martin P, Cencini E, Kamdar M, Link BK, Logothetis CN, Herrera AF, Friedberg JW, Kahl BS, Luminari S, Zinzani PL, Lossos IS. Alderuccio JP, et al. Among authors: sandoval sus j. Blood Adv. 2022 Apr 12;6(7):2035-2044. doi: 10.1182/bloodadvances.2021006844. Blood Adv. 2022. PMID: 35196377 Free PMC article.
35 results